Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 4/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.52 |
| ▸ | SOD1 | P00441 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7566159 | 0.90 | HRH3 (0.58) | KMT2AMEN1HTR1AHRH3HTR7 | |
| SCHEMBL11736036 | 0.84 | DRD2 (0.60) | KMT2AMEN1HRH3HTR7ALDH1A1 | |
| SCHEMBL5010657 | 0.84 | MAPT (0.61) | KMT2AMEN1ITGB3ITGA2BHTR1A | |
| SCHEMBL23407829 | 0.83 | KMT2A (0.56) | KMT2AMEN1HRH3ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1375787 | 0.83 | KMT2A (0.59) | KMT2AMEN1ITGB3ITGA2BHTR7 | |
| SCHEMBL17807164 | 0.83 | HRH3 (0.58) | KMT2AMEN1HTR1AHRH3ALDH1A1 | |
| SCHEMBL2114983 | 0.82 | HTR1A (0.73) | HTR1AHTR7ALDH1A1MAPT | |
| SCHEMBL6003242 | 0.82 | KMT2A (0.54) | KMT2AMEN1HTR1AHRH3ALDH1A1 | |
| SCHEMBL17429549 | 0.82 | HRH3 (0.60) | KMT2AHRH3ALDH1A1MAPTNPC1 | |
| SCHEMBL17669252 | 0.82 | MAPT (0.71) | KMT2AMEN1ALDH1A1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008093920-A2 | 1,2-DIHYDRO-1-OXOPHTHALAZINYL DERIVATIVES HAVING BIOLOGICAL ACTIVITY ON SEROTONIN RECEPTORS 5-HT2A AND 5-HT2C, AND PREPARATION THEREOF | DONGBU HITEK CO., LTD. (KR) | 2008-08-07 | — | — | WO | disclosed |
| EP-1383772-B1 | NITROGEN-BASED CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MED CENTER (US) | 2006-08-30 | — | — | EP | disclosed |
| CN-1246323-C | Nitrogen-based camptothecin derivatives | CALIFORNIA PACIFIC MED CENTER (US) | 2006-03-22 | — | — | CN | disclosed |
| EP-1581216-A1 | KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES BY INCREASING THE NUMBER OF ISLETS OF LANGERHANS CELLS | MERCK PATENT GmbH (DE) | 2005-10-05 | — | — | EP | disclosed |
| US-6933302-B2 | Nitrogen-based homo-camptothecin derivatives | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2005-08-23 | — | — | US | disclosed |
| US-6855720-B2 | Nitrogen-based camptothecin derivatives | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2005-02-15 | — | — | US | disclosed |
| US-6825207-B2 | ANTICANCER AGENTS | CALIFORNIA PACIFIC MEDICAL CENTER | 2004-11-30 | — | — | US | disclosed |
| WO-2004060368-A1 | KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES BY INCREASING THE NUMBER OF ISLETS OF LANGERHANS CELLS | MERCK PATENT GMBH (DE) | 2004-07-22 | — | — | WO | disclosed |
| CN-1511159-A | Nitrogen-based camptothecin derivatives | ����������̫ƽ��ҽѧ���� | 2004-07-07 | — | — | CN | disclosed |
| US-20040063740-A1 | For treatment of cancer | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | 2004-04-01 | — | — | US | disclosed |
| EP-1383772-A2 | NITROGEN-BASED CAMPTOTHECIN DERIVATIVES | California Pacific Medical Center (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2003101998-A1 | NITROGEN-BASED HOMO-CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2003-12-11 | — | — | WO | disclosed |
| US-20030073698-A1 | Nitrogen-based camptothecin derivatives | US ARMY, SECRETARY OF THE ARMY | 2003-04-17 | — | — | US | disclosed |
| US-20030032624-A1 | Nitrogen-based camptothecin derivatives | US ARMY, SECRETARY OF THE ARMY | 2003-02-13 | — | — | US | disclosed |
| WO-2002070525-A2 | NITROGEN-BASED CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2002-09-12 | — | — | WO | disclosed |
| US-6403604-B1 | ANTITUMOR | CALIFORNIA PACIFIC MEDICAL CENTER | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063740-A1 | For treatment of cancer | MGMT, PAICS, DCK | KMT2A 2430/4885MEN1 114/4885ITGB3 1967/4885 |
| US-20030073698-A1 | Nitrogen-based camptothecin derivatives | DCK, NEK11, NME1 | KMT2A 2819/4885MEN1 1506/4885ITGB3 3573/4885 |
| US-20030032624-A1 | Nitrogen-based camptothecin derivatives | DCK, NEK11, NME1 | KMT2A 2819/4885MEN1 1506/4885ITGB3 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.